438 related articles for article (PubMed ID: 15743836)
1. Vascular endothelial growth factor D is dispensable for development of the lymphatic system.
Baldwin ME; Halford MM; Roufail S; Williams RA; Hibbs ML; Grail D; Kubo H; Stacker SA; Achen MG
Mol Cell Biol; 2005 Mar; 25(6):2441-9. PubMed ID: 15743836
[TBL] [Abstract][Full Text] [Related]
2. VEGF-D deficiency in mice does not affect embryonic or postnatal lymphangiogenesis but reduces lymphatic metastasis.
Koch M; Dettori D; Van Nuffelen A; Souffreau J; Marconcini L; Wallays G; Moons L; Bruyère F; Oliviero S; Noel A; Foidart JM; Carmeliet P; Dewerchin M
J Pathol; 2009 Nov; 219(3):356-64. PubMed ID: 19718705
[TBL] [Abstract][Full Text] [Related]
3. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice.
Veikkola T; Jussila L; Makinen T; Karpanen T; Jeltsch M; Petrova TV; Kubo H; Thurston G; McDonald DM; Achen MG; Stacker SA; Alitalo K
EMBO J; 2001 Mar; 20(6):1223-31. PubMed ID: 11250889
[TBL] [Abstract][Full Text] [Related]
4. Molecular control of lymphatic metastasis.
Achen MG; Stacker SA
Ann N Y Acad Sci; 2008; 1131():225-34. PubMed ID: 18519975
[TBL] [Abstract][Full Text] [Related]
5. Differential in vivo and in vitro expression of vascular endothelial growth factor (VEGF)-C and VEGF-D in tumors and its relationship to lymphatic metastasis in immunocompetent rats.
Krishnan J; Kirkin V; Steffen A; Hegen M; Weih D; Tomarev S; Wilting J; Sleeman JP
Cancer Res; 2003 Feb; 63(3):713-22. PubMed ID: 12566318
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins.
Karkkainen MJ; Haiko P; Sainio K; Partanen J; Taipale J; Petrova TV; Jeltsch M; Jackson DG; Talikka M; Rauvala H; Betsholtz C; Alitalo K
Nat Immunol; 2004 Jan; 5(1):74-80. PubMed ID: 14634646
[TBL] [Abstract][Full Text] [Related]
7. Lymphangiogenesis and its relationship with lymphatic metastasis and prognosis in malignant melanoma.
Liu B; Ma J; Wang X; Su F; Li X; Yang S; Ma W; Zhang Y
Anat Rec (Hoboken); 2008 Oct; 291(10):1227-35. PubMed ID: 18561194
[TBL] [Abstract][Full Text] [Related]
8. Tumor-induced lymphangiogenesis: a target for cancer therapy?
Thiele W; Sleeman JP
J Biotechnol; 2006 Jun; 124(1):224-41. PubMed ID: 16497404
[TBL] [Abstract][Full Text] [Related]
9. Deficiency of vascular endothelial growth factor-D does not affect murine adipose tissue development.
Lijnen HR; Frederix L; Van Hoef B; Dewerchin M
Biochem Biophys Res Commun; 2009 Jan; 378(2):255-8. PubMed ID: 19022221
[TBL] [Abstract][Full Text] [Related]
10. [Characterization of markers and growth factors for lymphatic endothelium].
Waś H
Postepy Biochem; 2005; 51(2):209-14. PubMed ID: 16209358
[TBL] [Abstract][Full Text] [Related]
11. Lymphangiogenesis of normal endometrium and endometrial adenocarcinoma.
Donoghue JF; Lederman FL; Susil BJ; Rogers PA
Hum Reprod; 2007 Jun; 22(6):1705-13. PubMed ID: 17347164
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma.
Jüttner S; Wissmann C; Jöns T; Vieth M; Hertel J; Gretschel S; Schlag PM; Kemmner W; Höcker M
J Clin Oncol; 2006 Jan; 24(2):228-40. PubMed ID: 16344322
[TBL] [Abstract][Full Text] [Related]
13. Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody.
Pytowski B; Goldman J; Persaud K; Wu Y; Witte L; Hicklin DJ; Skobe M; Boardman KC; Swartz MA
J Natl Cancer Inst; 2005 Jan; 97(1):14-21. PubMed ID: 15632376
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3.
Mäkinen T; Jussila L; Veikkola T; Karpanen T; Kettunen MI; Pulkkanen KJ; Kauppinen R; Jackson DG; Kubo H; Nishikawa S; Ylä-Herttuala S; Alitalo K
Nat Med; 2001 Feb; 7(2):199-205. PubMed ID: 11175851
[TBL] [Abstract][Full Text] [Related]
15. Vascular endothelial growth factor-a promotes peritumoral lymphangiogenesis and lymphatic metastasis.
Björndahl MA; Cao R; Burton JB; Brakenhielm E; Religa P; Galter D; Wu L; Cao Y
Cancer Res; 2005 Oct; 65(20):9261-8. PubMed ID: 16230387
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor C stimulates progression of human gastric cancer via both autocrine and paracrine mechanisms.
Kodama M; Kitadai Y; Tanaka M; Kuwai T; Tanaka S; Oue N; Yasui W; Chayama K
Clin Cancer Res; 2008 Nov; 14(22):7205-14. PubMed ID: 19010837
[TBL] [Abstract][Full Text] [Related]
17. Correlation between lymph node metastasis and the expression of VEGF-C, VEGF-D and VEGFR-3 in T1 lung adenocarcinoma.
Maekawa S; Iwasaki A; Shirakusa T; Enatsu S; Kawakami T; Kuroki M; Kuroki M
Anticancer Res; 2007; 27(6A):3735-41. PubMed ID: 17970036
[TBL] [Abstract][Full Text] [Related]
18. VEGFR-3 ligand-binding and kinase activity are required for lymphangiogenesis but not for angiogenesis.
Zhang L; Zhou F; Han W; Shen B; Luo J; Shibuya M; He Y
Cell Res; 2010 Dec; 20(12):1319-31. PubMed ID: 20697430
[TBL] [Abstract][Full Text] [Related]
19. Plasmin activates the lymphangiogenic growth factors VEGF-C and VEGF-D.
McColl BK; Baldwin ME; Roufail S; Freeman C; Moritz RL; Simpson RJ; Alitalo K; Stacker SA; Achen MG
J Exp Med; 2003 Sep; 198(6):863-8. PubMed ID: 12963694
[TBL] [Abstract][Full Text] [Related]
20. Expression of VEGFR-3 and 5'-nase in regenerating lymphatic vessels of the cutaneous wound healing.
Ji RC; Miura M; Qu P; Kato S
Microsc Res Tech; 2004 Jun; 64(3):279-86. PubMed ID: 15452895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
